Today, University of Rochester President Joel Seligman announced two extraordinary gifts from The Wegman Family Charitable Foundation (WFCF): a $10 million lead gift to the University’s Institute for Data Science and a $7 million gift to support Golisano Children’s Hospital. Together with previous gifts to several programs across the University campuses, today’s announcement brings to $20 million the WFCF’s total contributions to the University’s comprehensive campaign. In recognition of this support for the Institute for Data Science, the Institute’s new landmark building will bear the Wegmans name.
Two UR studies have been taped by Science magazine as among last year’s most important scientific breakthroughs. Naked mole rats – animals that may hold the key to new cancer treatments – were named Vertebrate of the Year, while research that shows that the brain cleans itself while we sleep was named one of the Breakthroughs of the Year.
A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease. These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.
Palo Alto, CA – March 6, 2014 – iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, today announced a partnership transaction with Norwest Venture Partners (NVP), a global, multi-stage investment firm with $3.7 billion in capital under management. iCardiac will leverage the extensive strategic resources NVP has to offer to aggressively pursue significant growth opportunities and serve the rapidly growing needs of its pharmaceutical and medical device clients worldwide. Also as part of today’s announcement, two of NVP’s healthcare investment leaders, Dr. Ryan Harris and Dr. Robert Mittendorff, will join the Company’s board of directors.
The average cost to develop a new drug is about $1.2B and requires 10 to 15 years of development time.* iCardiac’s unique and proprietary technology allows CROs and pharmaceutical sponsors to obtain cardiac safety assessment results with less variance, resulting in smaller sample sizes and less development time. iCardiac is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. It currently serves seven of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.
More than 150 entrepreneurs and venture capitalists from throughout New York State gathered at Brighton’s ARTISANworks Tuesday evening to network and to hear some Rochester success stories. Organized by the Upstate Venture Association of New York (UVANY), the event featured an introductory presentation on “The New Rochester” by Richard Glaser and an interactive panel discussion featuring Mike Totterman (iCardiac), David Chauncey (vNomics), Tim Wilson (Arnold Magnetics), and Chris Modesti (Biomaxx). The panel was moderated by Will Hoy (Secrest & Emery). The venue perfectly captured the energy and creativity present in the room. The picture, above, was taken seconds before the UR Ventures banner stand noisily imploded.
Everyone is talking about Dr. Nedergaard’s discovery. We can’t blame them. This has huge potential. But don’t take our word for it . . . .
NIH News Update:
Stephen Dewhurst – 11 January 2014
“However beautiful the strategy, you should occasionally look at the results.” – Winston Churchill
Every organization needs a clearly articulated mission, a vision of where it wants to go, and a plan of how it will achieve that vision. That strategic plan is the roadmap for the future – and to be effective, its implementation should be monitored continuously until goals are met.
The reality is that we live in a world of short attention spans. All too often, we make plans, set them in motion and then walk away. Job done. And only much later do we look at the results – often to our dismay.
Goodnight. Sleep Clean.
By Maria Konnikova Jan. 11, 2014
SLEEP seems like a perfectly fine waste of time. Why would our bodies evolve to spend close to one-third of our lives completely out of it, when we could instead be doing something useful or exciting? Something that would, as an added bonus, be less likely to get us killed back when we were sleeping on the savanna?
“Sleep is such a dangerous thing to do, when you’re out in the wild,” Maiken Nedergaard, a Danish biologist who has been leading research into sleep function at the University of Rochester’s medical school, told me. “It has to have a basic evolutional function. Otherwise it would have been eliminated.”
NEW ORLEANS & ROCHESTER, N.Y.–(BUSINESS WIRE)–MiniVax, Inc. (New Orleans, LA) and the University of Rochester (Rochester, NY) announce that they have entered into an exclusive option agreement with agreed licensing terms to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia (PCP). The antibody of interest is a product of research conducted at the University of Rochester. PCP is a life-threatening, fungal respiratory infection that affects patients with weakened immune systems such as those suffering from HIV/AIDS, receiving organ transplants, and undergoing chemotherapy.
Companies interested in entering should have a scalable business concept with high growth potential. Companies must be early-stage, as defined at the time of application by having less than $250,000 of outside cash investment and less than $500,000 in cumulative revenue (excluding research grants).
The first place winner receives a $25,000 cash prize plus marketing and business incubation services. Second and third-place winners receive smaller amounts of cash and services. The runners-up receive marketing and business services.